埃沃洛库马布在现实环境中的有效性:来自泛欧洲观察海曼斯研究的奥地利数据
Christoph Ebenbichler1, Heinz Drexel2, Ursula Hanusch3
1Department of Internal Medicine I, Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. Christoph.Ebenbichler@i-med.ac.at.
Wiener klinische Wochenschrift
|July 31, 2023
概括
在奥地利患者中,Evolocumab显著降低了LDL-C,达到目标水平的65%. 观察到高持久性,证明了其在治疗脱脂症的有效性,即使没有背景降脂疗法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据 现实世界的证据
背景情况:
- 在12个欧洲国家对evolocumab进行现实研究,重点是奥地利患者数据.
- 检查了患者开始使用evolocumab的临床特征和失脂症管理.
研究的目的:
- 分析evolocumab在现实世界奥地利环境中的有效性和持续性.
- 评估降脂疗法 (LLT) 的使用和低密度脂蛋白胆固醇 (LDL-C) 目标的实现.
主要方法:
- 收集了来自同意的成年人的数据,最多在evolocumab开始前6个月和开始后30个月.
- 从医疗记录中提取了患者的特征,LLT (他/ezetimibe) 和脂质值.
主要成果:
- 纳入了363名奥地利患者; 52%的患者开始使用evolocumab,没有背景LLT.
- 平均LDL-C在3个月内下降了59%至58毫克/分升,随着时间的推移而持续.
- 65%的患者达到LDL-C<55 mg/dL;在12个月和30个月内持久率≥90%.
结论:
- 奥地利的患者开始使用evolocumab,LDL-C水平比指导目标高3倍.
- 埃沃洛库马布证明了快速,持续的LDL-C降低和高持久性.
- 与他类药物/ezetimibe联合治疗改善了LDL-C目标的实现,降低了心血管风险.
相关概念视频
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
01:19Pharmacovigilance
891
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
891
01:16Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
01:16Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K